Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias.

Bourrié B, Brassard DL, Cosnier-Pucheu S, Zilberstein A, Yu K, Levit M, Morrison JG, Perreaut P, Jegham S, Hilairet S, Bouaboula M, Penarier G, Guiot C, Larroze-Chicot P, Laurent G, Demur C, Casellas P.

Leuk Lymphoma. 2013 Jul;54(7):1488-99. doi: 10.3109/10428194.2012.745071. Epub 2012 Dec 3.

PMID:
23121564
2.

Transcriptome response of enterocytes to dietary lipids: impact on cell architecture, signaling, and metabolism genes.

Béaslas O, Torreilles F, Casellas P, Simon D, Fabre G, Lacasa M, Delers F, Chambaz J, Rousset M, Carrière V.

Am J Physiol Gastrointest Liver Physiol. 2008 Nov;295(5):G942-52. doi: 10.1152/ajpgi.90237.2008. Epub 2008 Aug 28.

3.

Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells.

Voland C, Bord A, Péleraux A, Pénarier G, Carrière D, Galiègue S, Cvitkovic E, Jbilo O, Casellas P.

Mol Cancer Ther. 2006 Sep;5(9):2149-57.

4.

The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.

Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Péleraux A, Pénarier G, Soubrié P, Le Fur G, Galiègue S, Casellas P.

FASEB J. 2005 Sep;19(11):1567-9. Epub 2005 Jul 11.

PMID:
16009704
5.

Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation.

Bouaboula M, Hilairet S, Marchand J, Fajas L, Le Fur G, Casellas P.

Eur J Pharmacol. 2005 Jul 11;517(3):174-81.

PMID:
15987634
6.

Sigma receptor ligands: applications in inflammation and oncology.

Bourrie B, Bribes E, Derocq JM, Vidal H, Casellas P.

Curr Opin Investig Drugs. 2004 Nov;5(11):1158-63. Review.

PMID:
15573866
7.

Expression of the peripheral benzodiazepine receptor triggers thymocyte differentiation.

Rochard P, Galiegue S, Tinel N, Peleraux A, Bord A, Jbilo O, Casellas P.

Gene Expr. 2004;12(1):13-27.

8.

SR31747A: a peripheral sigma ligand with potent antitumor activities.

Casellas P, Galiegue S, Bourrie B, Ferrini JB, Jbilo O, Vidal H.

Anticancer Drugs. 2004 Feb;15(2):113-8. Review.

PMID:
15075666
9.

Immunohistochemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival.

Galiègue S, Casellas P, Kramar A, Tinel N, Simony-Lafontaine J.

Clin Cancer Res. 2004 Mar 15;10(6):2058-64.

10.

Immunohistochemical assessment of the peripheral benzodiazepine receptor in human tissues.

Bribes E, Carrière D, Goubet C, Galiègue S, Casellas P, Simony-Lafontaine J.

J Histochem Cytochem. 2004 Jan;52(1):19-28.

PMID:
14688214
11.

Transcriptomic classification of antitumor agents: application to the analysis of the antitumoral effect of SR31747A.

Ferrini JB, Jbilo O, Peleraux A, Combes T, Vidal H, Galiegue S, Casellas P.

Gene Expr. 2003;11(3-4):125-39.

12.

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.

Cancer Res. 2003 Sep 15;63(18):5978-91. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.

13.

Identification and pharmacological characterization of SRBP-2: a novel SR31747A-binding protein.

Vidal H, Mondesert G, Galiègue S, Carrière D, Dupuy PH, Carayon P, Combes T, Bribes E, Simony-Lafontaine J, Kramar A, Loison G, Casellas P.

Cancer Res. 2003 Aug 15;63(16):4809-18.

14.

Ligands of the peripheral benzodiazepine receptor have therapeutic effects in pneumopathies in vivo.

Bribes E, Bourrie B, Casellas P.

Immunol Lett. 2003 Sep 8;88(3):241-7.

PMID:
12941483
15.

The peripheral benzodiazepine receptor: a promising therapeutic drug target.

Galiegue S, Tinel N, Casellas P.

Curr Med Chem. 2003 Aug;10(16):1563-72. Review.

PMID:
12871127
16.
17.

Mutation analysis in the coding sequence of thymidine kinase 1 in breast and colorectal cancer.

Gilles SI, Romain S, Casellas P, Ouafik L, Fina F, Combes T, Vuaroquaux V, Seitz JF, Bonnier P, Galiègue S, Carayon P, Martin PM.

Int J Biol Markers. 2003 Jan-Mar;18(1):1-6.

PMID:
12699056
18.

Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716.

Hilairet S, Bouaboula M, Carrière D, Le Fur G, Casellas P.

J Biol Chem. 2003 Jun 27;278(26):23731-7. Epub 2003 Apr 10.

19.

[Exploitation of expression profiles: examples in oncology].

Galiègue S, Casellas P.

J Soc Biol. 2002;196(4):313-5. Review. French.

PMID:
12645302
20.

SR31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivo.

Berthois Y, Bourrié B, Galiègue S, Vidal H, Carayon P, Martin PM, Casellas P.

Br J Cancer. 2003 Feb 10;88(3):438-46.

21.

Involvement of the peripheral benzodiazepine receptor in the development of cutaneous pathology in Mrl/Lpr mice.

Bribes E, Galiegue S, Bourrie B, Casellas P.

Immunol Lett. 2003 Jan 2;85(1):13-8.

PMID:
12505191
22.

SSR125329A, a high affinity sigma receptor ligand with potent anti-inflammatory properties.

Bourrié B, Bribes E, De Nys N, Esclangon M, Garcia L, Galiègue S, Lair P, Paul R, Thomas C, Vernières JC, Casellas P.

Eur J Pharmacol. 2002 Dec 5;456(1-3):123-31.

PMID:
12450578
23.

A DNA microarray-based approach to elucidate the effects of the immunosuppressant SR31747A on gene expression in Saccharomyces cerevisiae.

Cinato E, Péléraux A, Silve S, Galiègue S, Dhers C, Picard C, Jbilo O, Loison G, Casellas P.

Gene Expr. 2002;10(5-6):213-30.

24.

Expression profile and up-regulation of PRAX-1 mRNA by antidepressant treatment in the rat brain.

Chardenot P, Roubert C, Galiègue S, Casellas P, Le Fur G, Soubrié P, Oury-Donat F.

Mol Pharmacol. 2002 Dec;62(6):1314-20.

PMID:
12435798
25.

Involvement of the peripheral benzodiazepine receptor in the development of rheumatoid arthritis in Mrl/lpr mice.

Bribes E, Bourrie B, Esclangon M, Galiegue S, Vidal H, Casellas P.

Eur J Pharmacol. 2002 Sep 27;452(1):111-22.

PMID:
12323392
26.

International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.

Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG.

Pharmacol Rev. 2002 Jun;54(2):161-202. Review.

PMID:
12037135
27.

Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo.

Ouafik L, Sauze S, Boudouresque F, Chinot O, Delfino C, Fina F, Vuaroqueaux V, Dussert C, Palmari J, Dufour H, Grisoli F, Casellas P, Brünner N, Martin PM.

Am J Pathol. 2002 Apr;160(4):1279-92.

28.

Peripheral benzodiazepine receptors and mitochondrial function.

Casellas P, Galiegue S, Basile AS.

Neurochem Int. 2002 May;40(6):475-86. Review.

PMID:
11850104
29.

Peripheral benzodiazepine receptor mapping in rat kidney. Effects of angiotensin II-induced hypertension.

Bribes E, Casellas P, Vidal H, Dussossoy D, Casellas D.

J Am Soc Nephrol. 2002 Jan;13(1):1-9.

30.

Expression pattern of sigma receptor 1 mRNA and protein in mammalian retina.

Ola MS, Moore P, El-Sherbeny A, Roon P, Agarwal N, Sarthy VP, Casellas P, Ganapathy V, Smith SB.

Brain Res Mol Brain Res. 2001 Nov 1;95(1-2):86-95.

31.

Expression pattern of the type 1 sigma receptor in the brain and identity of critical anionic amino acid residues in the ligand-binding domain of the receptor.

Seth P, Ganapathy ME, Conway SJ, Bridges CD, Smith SB, Casellas P, Ganapathy V.

Biochim Biophys Acta. 2001 Jul 25;1540(1):59-67.

32.

Transient protection by peripheral benzodiazepine receptors during the early events of ultraviolet light-induced apoptosis.

Stoebner PE, Carayon P, Casellas P, Portier M, Lavabre-Bertrand T, Cuq P, Cano JP, Meynadier J, Meunier L.

Cell Death Differ. 2001 Jul;8(7):747-53.

33.

Monitoring cellular responses to Listeria monocytogenes with oligonucleotide arrays.

Cohen P, Bouaboula M, Bellis M, Baron V, Jbilo O, Poinot-Chazel C, Galiègue S, Hadibi EH, Casellas P.

J Biol Chem. 2000 Apr 14;275(15):11181-90.

34.

Immunocytochemical assessment of sigma-1 receptor and human sterol isomerase in breast cancer and their relationship with a series of prognostic factors.

Simony-Lafontaine J, Esslimani M, Bribes E, Gourgou S, Lequeux N, Lavail R, Grenier J, Kramar A, Casellas P.

Br J Cancer. 2000 Jun;82(12):1958-66.

35.

Characterization of NPY receptors controlling lipolysis and leptin secretion in human adipocytes.

Serradeil-Le Gal C, Lafontan M, Raufaste D, Marchand J, Pouzet B, Casellas P, Pascal M, Maffrand JP, Le Fur G.

FEBS Lett. 2000 Jun 16;475(2):150-6.

37.

A beneficial aspect of a CB1 cannabinoid receptor antagonist: SR141716A is a potent inhibitor of macrophage infection by the intracellular pathogen Brucella suis.

Gross A, Terraza A, Marchant J, Bouaboula M, Ouahrani-Bettache S, Liautard JP, Casellas P, Dornand J.

J Leukoc Biol. 2000 Mar;67(3):335-44.

PMID:
10733093
38.

The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment.

Bourrié B, Bribes E, Esclangon M, Garcia L, Marchand J, Thomas C, Maffrand JP, Casellas P.

Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12855-9.

39.

Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528.

Shire D, Calandra B, Bouaboula M, Barth F, Rinaldi-Carmona M, Casellas P, Ferrara P.

Life Sci. 1999;65(6-7):627-35. Review.

PMID:
10462063
40.

Colocalization of sterol isomerase and sigma(1) receptor at endoplasmic reticulum and nuclear envelope level.

Dussossoy D, Carayon P, Belugou S, Feraut D, Bord A, Goubet C, Roque C, Vidal H, Combes T, Loison G, Casellas P.

Eur J Biochem. 1999 Jul;263(2):377-86.

41.
42.

The expression of peripheral benzodiazepine receptors in human skin: the relationship with epidermal cell differentiation.

Stoebner PE, Carayon P, Penarier G, Fréchin N, Barnéon G, Casellas P, Cano JP, Meynadier J, Meunier L.

Br J Dermatol. 1999 Jun;140(6):1010-6.

PMID:
10354064
43.
44.
46.
47.

SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist.

Portier M, Rinaldi-Carmona M, Pecceu F, Combes T, Poinot-Chazel C, Calandra B, Barth F, le Fur G, Casellas P.

J Pharmacol Exp Ther. 1999 Feb;288(2):582-9.

PMID:
9918562
48.

Cloning and characterization of PRAX-1. A new protein that specifically interacts with the peripheral benzodiazepine receptor.

Galiègue S, Jbilo O, Combes T, Bribes E, Carayon P, Le Fur G, Casellas P.

J Biol Chem. 1999 Jan 29;274(5):2938-52.

49.

Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system.

Rinaldi-Carmona M, Le Duigou A, Oustric D, Barth F, Bouaboula M, Carayon P, Casellas P, Le Fur G.

J Pharmacol Exp Ther. 1998 Dec;287(3):1038-47.

PMID:
9864290
50.

Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells.

Vita N, Oury-Donat F, Chalon P, Guillemot M, Kaghad M, Bachy A, Thurneyssen O, Garcia S, Poinot-Chazel C, Casellas P, Keane P, Le Fur G, Maffrand JP, Soubrie P, Caput D, Ferrara P.

Eur J Pharmacol. 1998 Nov 6;360(2-3):265-72.

PMID:
9851594

Supplemental Content

Loading ...
Support Center